Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Taysha Gene Therapies (TSHA) EPS (Basic): 2022-2025

Historic EPS (Basic) for Taysha Gene Therapies (TSHA) over the last 4 years, with Sep 2025 value amounting to -$0.09.

  • Taysha Gene Therapies' EPS (Basic) rose 10.00% to -$0.09 in Q3 2025 from the same period last year, while for Sep 2025 it was -$0.33, marking a year-over-year decrease of 152.38%. This contributed to the annual value of -$0.36 for FY2024, which is 62.50% up from last year.
  • Latest data reveals that Taysha Gene Therapies reported EPS (Basic) of -$0.09 as of Q3 2025, which was down 0.00% from -$0.09 recorded in Q2 2025.
  • In the past 5 years, Taysha Gene Therapies' EPS (Basic) ranged from a high of $0.92 in Q4 2023 and a low of -$1.32 during Q1 2022.
  • In the last 3 years, Taysha Gene Therapies' EPS (Basic) had a median value of -$0.09 in 2025 and averaged -$0.12.
  • In the last 5 years, Taysha Gene Therapies' EPS (Basic) skyrocketed by 192.93% in 2023 and then crashed by 107.61% in 2024.
  • Taysha Gene Therapies' EPS (Basic) (Quarterly) stood at -$0.99 in 2022, then spiked by 192.93% to $0.92 in 2023, then plummeted by 107.61% to -$0.07 in 2024, then increased by 10.00% to -$0.09 in 2025.
  • Its EPS (Basic) stands at -$0.09 for Q3 2025, versus -$0.09 for Q2 2025 and -$0.08 for Q1 2025.